Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo del documento
Publication year range
1.
Dermatol Ther ; 34(6): e15122, 2021 11.
Artículo en Inglés | MEDLINE | ID: mdl-34478210

RESUMEN

The study aims to evaluate the vismodegib treatment in local advanced (laBCC) and metastatic (mBCC) basal cell carcinoma. The data of 29 patients were retrospectively reviewed. The clinical and histopathological features of the patients and adverse events of vismodegib were recorded. Overall survival (OS) and progression-free survival (PFS) were evaluated with Kaplan-Meier analysis. The median follow-up period was 17 months (range: 1.6-57.3), and the median age at diagnosis 73 years (range: 39-88). The most common disease location was head and neck (86.2%), and the most common non-skin sites of disease were lymph nodes (13.8%), bone (13.8%), lung (6.9%), and brain (6.9%). Three (10.3%) patients had Gorlin's syndrome. The number of metastatic patients was 5 (17.2%). With vismodegib treatment, the complete response rate was 27.6%, partial response 55.2%, and stable response 10.3%. Treatment responses were most frequently seen within 2 months from the beginning of vismodegib. The median OS was 43.3 ± 9.0 months (25.6-61.1) for all patients. The median PFS in the laBCC was 15.7 ± 1.8 months (12.2-19.3), and 12.1 ± 4.6 months (2.9-21.2) in the mBCC. In the univariable analysis for the OS, only the treatment after the vismodegib was statistically significant, showing chemotherapy was better comparing to no treatment or surgery. The most common adverse events were fatigue-58.6%, muscle spasms-48.3%, alopecia-13.8%, and weight loss-13.8%. This real-life data study shows that vismodegib treatment in locally advanced and metastatic BCC was well tolerated and effective.


Asunto(s)
Antineoplásicos , Carcinoma Basocelular , Neoplasias Cutáneas , Anilidas/efectos adversos , Antineoplásicos/efectos adversos , Carcinoma Basocelular/tratamiento farmacológico , Carcinoma Basocelular/patología , Humanos , Piridinas , Estudios Retrospectivos , Neoplasias Cutáneas/patología
2.
Sci Rep ; 10(1): 3510, 2020 02 26.
Artículo en Inglés | MEDLINE | ID: mdl-32103096

RESUMEN

In this study, FeSO4 supplementation ranging from 0 to 4.5 mM, and MgSO4 supplementation ranging from 0 to 5.1 mM were investigated to observe the effect on the population dynamics, biochemical composition and fatty acid content of mixed microalgae grown in Anaerobic Liquid Digestate (ALD). Overall, 3.1 mM FeSO4 addition into ALD increased the total protein content 60% and led to highest biomass (1.56 g L-1) and chlorophyll-a amount (18.7 mg L-1) produced. Meanwhile, 0.4 mM MgSO4 addition increased the total carotenoid amount 2.2 folds and slightly increased the biomass amount. According to the microbial community analysis, Diphylleia rotans, Synechocystis PCC-6803 and Chlorella sorokiniana were identified as mostly detected species after confirmation with 4 different markers. The abundance of Chlorella sorokiniana and Synechocystis PCC-6803 increased almost 2 folds both in iron and magnesium addition. On the other hand, the dominancy of Diphylleia rotans was not affected by iron addition while drastically decreased (95%) with magnesium addition. This study helps to understand how the dynamics of symbiotic life changes if macro elements are added to the ALD and reveal that microalgae can adapt to adverse environmental conditions by fostering the diversity with a positive effect on high value product.


Asunto(s)
Compuestos Férricos/farmacología , Sulfato de Magnesio/farmacología , Microalgas/efectos de los fármacos , Proteínas Algáceas/metabolismo , Biomasa , Carotenoides/metabolismo , Chlorella/genética , Chlorella/crecimiento & desarrollo , Clorofila A/metabolismo , Ácidos Grasos/análisis , Ácidos Grasos/metabolismo , Microalgas/crecimiento & desarrollo , Microalgas/metabolismo , Análisis de Componente Principal , ARN Ribosómico 16S/genética , Simbiosis/efectos de los fármacos , Synechocystis/genética , Synechocystis/crecimiento & desarrollo , Regulación hacia Arriba/efectos de los fármacos
3.
Sci Rep ; 10(1): 11963, 2020 Jul 15.
Artículo en Inglés | MEDLINE | ID: mdl-32665644

RESUMEN

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda